Key result
Baseline renin levels were modestly associated with 5-year blood pressure stage progression in discovery cohorts (OR 1.33; 95% CI 1.14-1.56), but this finding was not replicated in the MDC cohort.
Why the study?
Hypertension is the leading risk factor for premature death worldwide, making the identification of modifiable causes an imperative task.
Do baseline levels of 79 cardiovascular proteins predict longitudinal blood pressure stage progression in individuals not on BP-lowering drugs?
Cohort (n=3,463)
Yes
Do baseline levels of 79 cardiovascular proteins predict longitudinal blood pressure stage progression in individuals not on BP-lowering drugs?
Effect estimate: OR 1.33 (95% CI 1.14-1.56)
p-value: p=5% FDR
A proteomic analysis of 79 cardiovascular proteins failed to identify any novel, robust biomarkers for longitudinal blood pressure progression over 5 years.
No takes yet. Share an insight, caveat, or question.
Does not support renin measurement for BP progression risk stratification; leaves open identification of robust proteomic biomarkers.
Lin et al. (2019) conducted a cohort in Hypertension (n=3,463). Baseline circulating protein levels (79 proteins) was evaluated on Blood pressure stage progression as per the 2017 AHA/ACC Guideline BP categories (OR 1.33, 95% CI 1.14-1.56, p=5% FDR). Baseline renin levels were modestly associated with 5-year blood pressure stage progression in discovery cohorts (OR 1.33; 95% CI 1.14-1.56), but this finding was not replicated in the MDC cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: